bf/NASDAQ:TRVI_icon.jpeg

NASDAQ:TRVI

Trevi Therapeutics, Inc.

  • Stock

6.90

−0.14%

−0.59

USD last updated 15/08 02:20:07

Last Close

7.49

14/08 20:01

Market Cap

186.65M

Beta: 0.69

Volume Today

1.81M

Avg: 82.90K

PE Ratio

−5.22

PFCF: −2.81

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.6-0.5-0.4-0.3-0.2-0.12019-08-122020-12-302021-12-302023-08-102024-11-14

    Revenue (Estimate*)

    0.000.000.010.010.012019-08-122020-12-302021-12-302023-08-102024-11-14

    *Estimate based on analyst consensus